The deal size was raised to $350M in common stock from $300M in common stock. JPMorgan, Morgan Stanley and Jefferies acted as joint book running managers for the offering.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AKRO:
- Akero Therapeutics price target raised to $96 from $46 at Morgan Stanley
- Akero Therapeutics price target raised to $73 from $56 at Canaccord
- Akero Shares Skyrocket as MASH Drug Delivers Game-Changing Results
- Akero Therapeutics price target raised to $80 from $65 at Citi
- Akero Therapeutics announces $300M common stock offering